MRCKα Activators
MRCKα Activators influence cellular processes by engaging with a variety of signaling pathways that regulate cytoskeletal dynamics and cell motility. Phorbol 12-myristate 13-acetate (PMA) directly activates protein kinase C, which can phosphorylate and enhance the activity of MRCKα, a kinase that modulates the actin cytoskeleton. Similarly, Forskolin raises intracellular cAMP levels, indirectly activating PKA, which can phosphorylate proteins that interact with MRCKα, leading to its enhanced activity. The non-hydrolyzable GTP analogue, GTPγS, sustains the activation of GTPases, upstream regulators of MRCKα, ensuring prolonged activation of MRCKα and its role in cytoskeletal reorganization.
Other compounds, such as Calyculin A, work by inhibiting phosphatases, the dephosphorylation of MRCKα or its substrates, thereby maintaining MRCKα in an active state. Growth factors like Epidermal Growth Factor initiate signaling cascades that activate Rho GTPases, which directly enhance MRCKαactivity. Lysophosphatidic acid and Sphingosine 1-phosphate engage G protein-coupled receptors to activate similar pathways. Jasplakinolide and Latrunculin A act on the actin cytoskeleton, with Jasplakinolide stabilizing actin filaments, potentially enhancing MRCKα's polymerization activity, and Latrunculin A disrupting polymerization, which may trigger compensatory activation of MRCKα. Furthermore, inhibitors like Y-27632 and ML-7 indirectly promote MRCKα activity by targeting other kinases involved in cytoskeletal dynamics, such as ROCK and MLCK. The inhibition of these kinases shifts regulatory balance towards MRCKα, enhancing its functional role in actin-myosin contraction. Blebbistatin, by inhibiting myosin II, can also create a feedback loop that results in the upregulation of MRCKα activity. Collectively, these MRCKα Activators play crucial roles in modulating the cytoskeletal architecture and cell movement by specifically influencing the activity of MRCKα through a variety of signaling pathways and molecular interactions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can enhance the phosphorylation of downstream targets, including MRCKα. PKC-mediated phosphorylation typically serves to regulate the actin cytoskeleton, which MRCKα is directly involved in modulating. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, leading to an increase in cAMP levels. Elevated cAMP activates PKA, which can phosphorylate substrates that interact with or regulate MRCKα, enhancing its activity in cytoskeletal rearrangement. | ||||||
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $465.00 | ||
GTPγS is a non-hydrolyzable analogue of GTP, binding and activating GTPase proteins without being consumed. Since MRCKα is regulated by GTPases, GTPγS can indirectly enhance MRCKα activity by sustaining the active GTP-bound state of its upstream regulators. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
As an inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A), Calyculin A prevents dephosphorylation of proteins, which may include substrates of MRCKα or MRCKα itself, leading to enhanced activity in cytoskeletal dynamics. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
LPA acts through its G protein-coupled receptors to activate Rho GTPases, which are known to interact with and activate MRCKα, enhancing its role in actin-myosin contractility. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P binds to its receptors, initiating signaling cascades that can lead to the activation of Rho GTPases and subsequent activation of MRCKα, influencing cytoskeletal rearrangements. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and can potentiate MRCKα activity by enhancing actin polymerization, a process that MRCKα is known to regulate. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Latrunculin A binds to actin monomers and prevents polymerization. This disruption can lead to compensatory mechanisms that activate MRCKα as the cell attempts to restore cytoskeletal integrity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that can lead to a compensatory increase in MRCKα activity since both ROCK and MRCKα are involved in regulating similar cytoskeletal processes. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK). Inhibition of MLCK can shift the balance of actomyosin contraction regulation towards MRCKα, indirectly enhancing its activity. | ||||||